MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

安捷伦Agilent InfinityLab 液相色谱/质量选择检测器 (LC/MSD) 系统专为提升分析可靠性和工作效率设计。该系统结合了质量选择性 ...